Genome-Wide Screening Identifies Gene AKR1C1 Critical for Resistance to Pirarubicin in Bladder Cancer

Simple Summary Bladder cancer is one of the most common malignant tumors in the urinary system. Pirarubicin (THP) perfusion therapy is an important treatment method for non-muscle-invasive bladder cancer. However, an increasing number of cases of recurrence or progression of bladder cancer caused by THP resistance have been reported. Therefore, we urgently need to find the critical genes that cause THP resistance in bladder cancer. In this study, we obtained the critical gene AKR1C1 that causes resistance of bladder cancer to THP via CRISPR/dCas9 SAM. This study not only verified that AKR1C1 can cause resistance of bladder cancer cells to THP both in in vivo and in vitro, but also found that THP treatment can gradually increase the expression of AKR1C1, thus causing resistance to the drug. In addition, we also found that aspirin, the AKR1C1 inhibitor, and tempol, the ROS scavenger, can effectively overcome the drug resistance caused by AKR1C1. Abstract Non-muscle-invasive bladder cancer (NMIBC) is a common tumor of the urinary system. Given its high rates of recurrence, progression, and drug resistance, NMIBC seriously affects the quality of life and limits the survival time of patients. Pirarubicin (THP) is a bladder infusion chemotherapy drug recommended by the guidelines for NMIBC. Although the widespread use of THP reduces the recurrence rate of NMIBC, 10–50% of patients still suffer from tumor recurrence, which is closely related to tumor resistance to chemotherapy drugs. This study was performed to screen the critical genes causing THP resistance in bladder cancer cell lines by using the CRISPR/dCas9-SAM system. Thus, AKR1C1 was screened. Results showed that the high expression of AKR1C1 could enhance the drug resistance of bladder cancer to THP both in vivo and in vitro. This gene could reduce the levels of 4-hydroxynonenal and reactive oxygen species (ROS) and resist THP-induced apoptosis. However, AKR1C1 did not affect the proliferation, invasion, or migration of the bladder cancer cells. Aspirin, which is an AKR1C1 inhibitor, could help reduce the drug resistance caused by AKR1C1. After receiving THP treatment, the bladder cancer cell lines could upregulate the expression of the AKR1C1 gene through the ROS/KEAP1/NRF2 pathway, leading to resistance to THP treatment. Using tempol, which is an inhibitor of ROS, could prevent the upregulation of AKR1C1 expression.

[1]  A. Jemal,et al.  Cancer statistics, 2023 , 2023, CA: a cancer journal for clinicians.

[2]  Xuenong Zou,et al.  Oxidative Stress and Intervertebral Disc Degeneration: Pathophysiology, Signaling Pathway, and Therapy , 2022, Oxidative Medicine and Cellular Longevity.

[3]  Lei-Sheng Jiang,et al.  Mitochondrial Dysfunction in Oxidative Stress‐Mediated Intervertebral Disc Degeneration , 2022, Orthopaedic surgery.

[4]  Wanqing Chen,et al.  Cancer statistics in China and United States, 2022: profiles, trends, and determinants , 2022, Chinese medical journal.

[5]  Hui Cao,et al.  Regulated Cell Death in Urinary Malignancies , 2021, Frontiers in Cell and Developmental Biology.

[6]  Q. Guo,et al.  Overview of human 20 alpha-hydroxysteroid dehydrogenase (AKR1C1): Functions, regulation, and structural insights of inhibitors. , 2021, Chemico-biological interactions.

[7]  Jun Fang,et al.  Development of a Selective Tumor-Targeted Drug Delivery System: Hydroxypropyl-Acrylamide Polymer-Conjugated Pirarubicin (P-THP) for Pediatric Solid Tumors , 2021, Cancers.

[8]  T. Penning,et al.  Aldo-Keto Reductases and Cancer Drug Resistance , 2021, Pharmacological Reviews.

[9]  K. Kuča,et al.  Novel CRISPR–Cas Systems: An Updated Review of the Current Achievements, Applications, and Future Research Perspectives , 2021, International journal of molecular sciences.

[10]  M. Kołaczkowski,et al.  Carbonyl Reduction Pathway in Hepatic In Vitro Metabolism of Anthracyclines: Impact of Structure on Biotransformation Rate. , 2021, Toxicology letters.

[11]  D. Hapangama,et al.  Fallopian tube epithelial cells express androgen receptor and have a distinct hormonal responsiveness when compared with endometrial epithelium. , 2020, Human reproduction.

[12]  Keming Zhang,et al.  Genome-scale CRISPR activation screening identifies a role of LRP8 in Sorafenib resistance in Hepatocellular carcinoma. , 2020, Biochemical and biophysical research communications.

[13]  D. Parekh,et al.  Utility and Validation of the AUA/SUO Risk Grouping for Non-muscle Invasive Bladder Cancer in a Contemporary Cohort. , 2020, The Journal of urology.

[14]  W. Oyen,et al.  Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer , 2019, European urology.

[15]  J. Costello,et al.  A Whole-genome CRISPR Screen Identifies a Role of MSH2 in Cisplatin-mediated Cell Death in Muscle-invasive Bladder Cancer. , 2019, European urology.

[16]  L. Watson,et al.  Comprehensive off-target analysis of dCas9-SAM-mediated HIV reactivation via long noncoding RNA and mRNA profiling , 2018, BMC Medical Genomics.

[17]  A. Shimizu,et al.  Prognostic utility of atypical mitoses in patients with breast cancer: A comparative study with Ki67 and phosphohistone H3 , 2018, Journal of surgical oncology.

[18]  J. Sfakianos,et al.  The evolution of bladder cancer genomics: What have we learned and how can we use it? , 2018, Urologic oncology.

[19]  Tohru Maeda,et al.  Oxidative DNA Damage Induced by Pirarubicin, an Anthracycline Anticancer Agent, in the Presence of Copper(II). , 2018, Anticancer research.

[20]  J. Rinn,et al.  An Integrated Genome-wide CRISPRa Approach to Functionalize lncRNAs in Drug Resistance , 2018, Cell.

[21]  Y. Miyaji,et al.  Prospective randomized controlled trial of postoperative early intravesical chemotherapy with pirarubicin (THP) for solitary non-muscle invasive bladder cancer comparing single and two-time instillation , 2018, World Journal of Urology.

[22]  Michael R. Green,et al.  CRISPR-Cas9–mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracy , 2017, Proceedings of the National Academy of Sciences.

[23]  Hong Wang,et al.  A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220. , 2017, Cancer research.

[24]  J. Witjes,et al.  MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER , 2016 .

[25]  Nir Hacohen,et al.  A genome-wide CRISPR screen identifies a restricted set of HIV host dependency factors , 2016, Nature Genetics.

[26]  Levi G. Lowder,et al.  Multiplexed Transcriptional Activation or Repression in Plants Using CRISPR-dCas9-Based Systems. , 2017, Methods in molecular biology.

[27]  Yukyung Jun,et al.  Rapid emergence and mechanisms of resistance by U87 glioblastoma cells to doxorubicin in an in vitro tumor microfluidic ecology , 2016, Proceedings of the National Academy of Sciences.

[28]  Kazuhiko Yoshida,et al.  Aldo-keto reductase 1C1 induced by interleukin-1β mediates the invasive potential and drug resistance of metastatic bladder cancer cells , 2016, Scientific Reports.

[29]  M. Bozza,et al.  Resveratrol Reverses Functional Chagas Heart Disease in Mice , 2016, PLoS pathogens.

[30]  T. Pierson,et al.  A CRISPR screen defines a signal peptide processing pathway required by flaviviruses , 2016, Nature.

[31]  Hakho Lee,et al.  Genome-wide CRISPR Screen in a Mouse Model of Tumor Growth and Metastasis , 2015, Cell.

[32]  T. Penning,et al.  Role of aldo–keto reductase family 1 (AKR1) enzymes in human steroid metabolism , 2014, Steroids.

[33]  Neville E. Sanjana,et al.  Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells , 2014, Science.

[34]  Q. Ding,et al.  Ki67 and TP53 expressions predict recurrence of non-muscle-invasive bladder cancer , 2014, Tumor Biology.

[35]  V. Čapkun,et al.  Prognostic value of Ki-67 proliferating index in triple negative breast carcinomas. , 2013, Pathology, research and practice.

[36]  S. Turk,et al.  Inhibitors of aldo-keto reductases AKR1C1-AKR1C4. , 2011, Current medicinal chemistry.

[37]  O. El-Kabbani,et al.  Inhibitors of human 20α-hydroxysteroid dehydrogenase (AKR1C1) , 2011, The Journal of Steroid Biochemistry and Molecular Biology.

[38]  Trevor M Penning,et al.  Aldo-keto reductase (AKR) superfamily: Genomics and annotation , 2009, Human Genomics.

[39]  Adam J. Bewick,et al.  Induction of 1C aldoketoreductases and other drug dose-dependent genes upon acquisition of anthracycline resistance , 2009, Pharmacogenetics and genomics.

[40]  Satoshi Endo,et al.  A salicylic acid-based analogue discovered from virtual screening as a potent inhibitor of human 20alpha-hydroxysteroid dehydrogenase. , 2007, Medicinal chemistry (Shariqah (United Arab Emirates)).

[41]  Kuang-Tai Kuo,et al.  Reversal of inflammation‐associated dihydrodiol dehydrogenases (AKR1C1 and AKR1C2) overexpression and drug resistance in nonsmall cell lung cancer cells by wogonin and chrysin , 2007, International journal of cancer.

[42]  N. Palackal,et al.  Activation of Polycyclic Aromatic Hydrocarbontrans-Dihydrodiol Proximate Carcinogens by Human Aldo-keto Reductase (AKR1C) Enzymes and Their Functional Overexpression in Human Lung Carcinoma (A549) Cells* , 2002, The Journal of Biological Chemistry.

[43]  V. Luu‐The,et al.  Characterization of a human 20alpha-hydroxysteroid dehydrogenase. , 2000, Journal of molecular endocrinology.

[44]  G. Prout,et al.  Treated history of noninvasive grade 1 transitional cell carcinoma. The National Bladder Cancer Group. , 1992, The Journal of urology.